{"slideshow_credits": null, "snippet": "It\u2019s not clear, though, how Mr. Bass\u2019s hedge fund, Hayman Capital, has an advantage over experienced generic firms, Robert Cyran of Reuters Breakingviews writes.", "abstract": "It\u2019s not clear, though, how Mr. Bass\u2019s hedge fund, Hayman Capital, has an advantage over experienced generic firms, Robert Cyran of Reuters Breakingviews writes.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 1, "organization": ""}], "original": "By ROBERT CYRAN"}, "web_url": "http://dealbook.nytimes.com/2015/02/11/kyle-bass-wields-new-weapon-in-challenging-drug-makers/", "lead_paragraph": null, "headline": {"main": "Kyle Bass Wields New Weapon in Challenging Drug Makers ", "kicker": "DealBook"}, "_id": "54dbaf9138f0d838b6ad6303", "word_count": "429", "multimedia": [{"height": 126, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 388, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-articleLarge.jpg", "legacy": {"xlarge": "images/2015/02/12/business/dbpix-bass/dbpix-bass-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "388"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-02-11T14:36:17Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Acorda Therapeutics Inc", "rank": "1"}, {"name": "organizations", "value": "Biogen Idec Inc", "rank": "2"}, {"name": "organizations", "value": "Celgene Corporation", "rank": "3"}, {"name": "organizations", "value": "Patent and Trademark Office (US)", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}, {"name": "subject", "value": "Hedge Funds", "rank": "2"}, {"name": "subject", "value": "Inventions and Patents", "rank": "3"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}